Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
GUD Stock Overview
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally.
Risk Analysis
No risks detected for GUD from our risk checks.
Knight Therapeutics Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$5.22 |
52 Week High | CA$5.74 |
52 Week Low | CA$5.01 |
Beta | 0.53 |
1 Month Change | -2.43% |
3 Month Change | 0.19% |
1 Year Change | -4.22% |
3 Year Change | -32.38% |
5 Year Change | -49.27% |
Change since IPO | 36.29% |
Recent News & Updates
Shareholder Returns
GUD | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | 1.4% | -0.3% | 0.3% |
1Y | -4.2% | -70.9% | -4.0% |
Return vs Industry: GUD exceeded the Canadian Pharmaceuticals industry which returned -70.9% over the past year.
Return vs Market: GUD matched the Canadian Market which returned -4.1% over the past year.
Price Volatility
GUD volatility | |
---|---|
GUD Average Weekly Movement | 2.5% |
Pharmaceuticals Industry Average Movement | 11.7% |
Market Average Movement | 10.0% |
10% most volatile stocks in CA Market | 17.3% |
10% least volatile stocks in CA Market | 4.4% |
Stable Share Price: GUD is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: GUD's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 660 | Samira Sakhia | https://www.gud-knight.com |
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation.
Knight Therapeutics Fundamentals Summary
GUD fundamental statistics | |
---|---|
Market Cap | CA$601.81m |
Earnings (TTM) | -CA$6.69m |
Revenue (TTM) | CA$261.22m |
2.3x
P/S Ratio-89.9x
P/E RatioIs GUD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GUD income statement (TTM) | |
---|---|
Revenue | CA$261.22m |
Cost of Revenue | CA$133.91m |
Gross Profit | CA$127.31m |
Other Expenses | CA$134.00m |
Earnings | -CA$6.69m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.058 |
Gross Margin | 48.74% |
Net Profit Margin | -2.56% |
Debt/Equity Ratio | 4.9% |
How did GUD perform over the long term?
See historical performance and comparisonValuation
Is GUD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GUD?
Other financial metrics that can be useful for relative valuation.
What is GUD's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | CA$601.81m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.8x |
Enterprise Value/EBITDA | 11.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GUD's PS Ratio compare to its peers?
GUD PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.9x |
Price-To-Sales vs Peers: GUD is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (1.9x).
Price to Earnings Ratio vs Industry
How does GUD's PE Ratio compare vs other companies in the Canadian Pharmaceuticals Industry?
Price-To-Sales vs Industry: GUD is expensive based on its Price-To-Sales Ratio (2.3x) compared to the Canadian Pharmaceuticals industry average (2x)
Price to Sales Ratio vs Fair Ratio
What is GUD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.3x |
Fair PS Ratio | 0.8x |
Price-To-Sales vs Fair Ratio: GUD is expensive based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).
Share Price vs Fair Value
What is the Fair Price of GUD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GUD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GUD's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GUD's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Knight Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
117.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GUD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GUD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GUD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GUD's revenue (6.3% per year) is forecast to grow slower than the Canadian market (7.3% per year).
High Growth Revenue: GUD's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GUD is forecast to be unprofitable in 3 years.
Discover growth companies
Past Performance
How has Knight Therapeutics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
4.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GUD is currently unprofitable.
Growing Profit Margin: GUD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GUD is unprofitable, but has reduced losses over the past 5 years at a rate of 4.5% per year.
Accelerating Growth: Unable to compare GUD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GUD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (118.1%).
Return on Equity
High ROE: GUD has a negative Return on Equity (-0.81%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Knight Therapeutics's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: GUD's short term assets (CA$331.0M) exceed its short term liabilities (CA$121.3M).
Long Term Liabilities: GUD's short term assets (CA$331.0M) exceed its long term liabilities (CA$44.5M).
Debt to Equity History and Analysis
Debt Level: GUD has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GUD's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: GUD's debt is well covered by operating cash flow (98.2%).
Interest Coverage: Insufficient data to determine if GUD's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Dividend
What is Knight Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GUD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GUD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GUD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GUD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GUD has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Samira Sakhia (53 yo)
5.83yrs
Tenure
CA$1,098,852
Compensation
Ms. Samira Sakhia, MBA, BCom, CPA, CA, has been the President at Knight Therapeutics Inc. since August 31, 2016 and served as its Chief Financial Officer since October 10, 2017 until March 30, 2020. She ha...
CEO Compensation Analysis
Compensation vs Market: Samira's total compensation ($USD850.70K) is below average for companies of similar size in the Canadian market ($USD1.24M).
Compensation vs Earnings: Samira's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: GUD's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
Experienced Board: GUD's board of directors are considered experienced (5.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GUD insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Knight Therapeutics Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Knight Therapeutics Inc.
- Ticker: GUD
- Exchange: TSX
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$601.809m
- Shares outstanding: 115.29m
- Website: https://www.gud-knight.com
Number of Employees
Location
- Knight Therapeutics Inc.
- 3400 De Maisonneuve Boulevard West
- Suite 1055
- Montreal
- Quebec
- H3Z 3B8
- Canada
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.